Category: Pharma Industry

News Alert: United Therapeutics Unveils 340B Contract Pharmacy Claims Submission Requirement

In Pharma IndustryApril 14, 2021

Drug manufacturer United Therapeutics on Monday launched phase two of its restrictions on 340B contract pharmacy, telling covered entities what they must do to keep getting 340B pricing from the company on its drugs when dispensed by the entities’ retail …

Gilead’s HIV Drug Reimbursement Cut Will be Devastating, 340B Covered Entities Say

In Pharma IndustryApril 13, 2021

Ron Shinkman

Drug manufacturer Gilead late last week announced a huge cut, effective Jan. 1, 2022, in pharmacy reimbursement for its HIV and hepatitis B medicines that uninsured individuals get for free through Gilead’s Advancing Access patient assistance program (PAP). 340B HIV/AIDS …

340B Sales Grew 18% from 2019 to 2020, Drug Industry Consulting Firm Says

In Pharma Industry, Research/ReportsApril 8, 2021

Tom Mirga

Drug industry consulting and contract research firm IQVIA reports that prescription drug sales at 340B-discounted prices grew 18.1% year-on-year from 2019 to 2020.

Please Login or Become a Paid Subscriber to View this Content

…

Origin Biosciences Posts Limited Distribution Notice on 340B Program Site

In Federal, Pharma Industry, RegulatoryMarch 30, 2021

Tom Mirga

The manufacturer of Nulibry, a recently approved, first-of-its-kind injectable treatment for a very rare, often fatal genetic disorder that typically appears soon after birth, has posted details about the limited distribution network for the drug on the U.S. Health Resources …

Merck Pitches Its Voluntary 340B Integrity Initiative to Providers as a Better Option than Audits

In Pharma IndustryMarch 25, 2021

Tom Mirga

Drug manufacturer Merck sent letters to 340B covered entities by email on Tuesday to provide background and answer questions about its request that entities voluntarily upload their contract pharmacy claims to a vendor’s software platform so they can be checked …

PhRMA: Providers Use 340B as “Slush Fund”

In Pharma IndustryMarch 11, 2021

Tom Mirga

The 340B program “attracts hospitals, clinics and for-profit pharmacies because it is easy for them to use the program as a slush fund to benefit their bottom lines, diverting money that could be used to help patients get better care …

News Flash: State Attorney General Orders Sanofi to Hand Over 340B Information

In Pharma Industry, StateMarch 9, 2021

Tom Mirga

Vermont State Attorney General T.J. Donovan (D) has issued a subpoena to drug manufacturer Sanofi “seeking certain information about Sanofi’s 340B program participation,” the company disclosed last week.

Please Login or Become a Paid Subscriber to

…

Orphan Drug Study’s Authors Say Findings May Warrant Lifting 340B Exemption

In Federal, Legislative, Pharma Industry, Research/ReportsMarch 4, 2021

Tom Mirga

More than 70 percent of U.S. spending on top-selling “partial orphan drugs”—drugs for rare diseases that also are approved to treat common diseases—is for non-orphan indications, a study in latest edition of Health Affairs concludes. Policymakers who “wish to decrease …

Generic Drug Manufacturer Posts 340B Refund Notice

In Federal, Pharma Industry, RegulatoryFebruary 18, 2021

Tom Mirga

Generic liquid drug manufacturer Pharmaceutical Associates, Inc. (PAI), has notified 340B covered entities on the U.S. Health Resources and Services Administration (HRSA) website about 340B overcharges and potential credit/rebill repayments regarding all of its products covering first through third quarters …

AstraZeneca Tells Court HHS’s 340B Enforcement Poses “Imminent Irreparable Harm”

In Federal, Judicial, Pharma IndustryFebruary 16, 2021

Tom Mirga

Drug manufacturer AstraZeneca on Friday asked the federal district judge in Delaware handling its 340B contract pharmacy lawsuit against the federal government either to issue a preliminary injunction in its favor or expedite court proceedings “to prevent imminent irreparable harm” …